Thus, these results suggest that activation of Notch1 signaling promotes the development of AAA by multiple mechanisms, and the γ-secretase inhibitor DBZ might be a new therapeutic target for treating AAA formation. Here, NOTCH1 is linked to triple-A syndrome.